Companies › Beijing Biotech
27 active drug programs in 41 registered trials: 40 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EB-DART-NK01 Allogeneic dual-target CAR-NK cells (DLL3/CD56, DLL3/GD2, or CD56/GD2) | DLL3, CD56, GD2 | Phase 1 | Small Cell Lung Cancer (SCLC) | Feb 2027 |
| EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) Allogeneic CAR-NK cells with dual-recognition CAR targeting MSLN and MUC1 | MSLN, MUC1 | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Feb 2027 |
| EB-G3B7-NK dual-target CAR-NK cells Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr | CD276, MSLN, EGFR, ERBB2, IL13RA2 | Phase 1 | Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) … | Feb 2027 |
| EB-NK-MF CAR-NK cells Dual-targeting CAR-NK cells engineered to target Mesothelin and Folate Receptor alpha (wit | MSLN, FOLR1, MUC16, TROP2 | Phase 1 | Advanced Solid Tumors; Epithelial Ovarian Cancer | Feb 2027 |
| Autologous BCMA/CD19 dual-target CAR-T module | – | Phase 1 | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Mar 2027 |
| Autologous BCMA/CD38 dual-target CAR-T module | – | Phase 1 | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Mar 2027 |
| Autologous CD19/CD20 dual-target CAR-T module | – | Phase 1 | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Mar 2027 |
| Autologous CD19/CD22 dual-target CAR-T module | – | Phase 1 | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Mar 2027 |
| Autologous anti-BCMA CAR-T cells CAR-T cell therapy targeting BCMA-expressing plasma cells | TNFRSF17 | Phase 1 | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS | Mar 2027 |
| Autologous anti-CD19 CAR-T cells CAR-T cell therapy targeting CD19-expressing B cells | CD19 | Phase 1 | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS; Scleroderma, Systemic | Mar 2027 |
| EB-DT-CAR-NK Dual-target CLDN18.2/HER2 CAR-NK cells | CLDN18, ERBB2 | Phase 1 | Advanced Gastric Adenocarcinoma | Mar 2027 |
| EB-DTNB-NK Dual-target GD2/B7-H3 CAR-NK cells with IL-15 support and inducible safety switch | GYPC, CD276 | Phase 1 | Relapsed Neuroblastoma | Mar 2027 |
| EB-DUALNK Dual-target CAR-NK cells (antigen pair to be selected from GD2, MUC1, PSMA, mesothelin) | – | Phase 1 | Epithelial Ovarian Cancer | Mar 2027 |
| EB-DUO-CAR-NK-CEA/GCC Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H | CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15 | Phase 1 | Colorectal Cancer; Colorectal Cancer Metastatic | Mar 2027 |
| EB-HC01 dual-target CAR-NK cells Allogeneic dual-target CAR-NK cells targeting HER2 and CEA/CEACAM5 | ERBB2, CEACAM5 | Phase 1 | Cholangiocarcinoma | Mar 2027 |
| EB-MF-CAR-NK-01 Dual-target CAR-NK cells recognizing mesothelin-positive tumor cells and FAP-positive stro | MSLN, FAP | Phase 1 | Malignant Pleural Mesotheliomas | Mar 2027 |
| EB-PT-CAR-NK-S Single-target CAR-NK cell therapy | – | Phase 1 | Advanced or Metastatic Solid Tumors | Mar 2027 |
| EBNK-1822H2 Dual-target CLDN18.2/HER2 CAR-NK cells | CLDN18A2, ERBB2 | Phase 1 | Recurrent or Metastatic Esophageal Adenocarcinoma | Mar 2027 |
| EGFR/HER2 Dual-Target CAR-NK Cells Allogeneic donor-derived NK cells engineered to express dual EGFR/HER2 chimeric antigen re | EGFR, ERBB2 | Phase 1 | Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Mar 2027 |
| ETB-DualNK-01 Dual-target anti-PSMA/PSCA CAR-NK cells | PSMA, PSCA | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Mar 2027 |
| Autologous dual-target CAR-T cells Patient-derived T cells engineered to recognize two tumor-associated antigens selected fro | – | Phase 1 | Advanced Unresectable | Apr 2027 |
| EB-701/CA9-NK Dual-target CD70/CAIX CAR-NK cells | CD70, CA9 | Phase 1 | Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Apr 2027 |
| EB-CAR30-NK CD30-targeted allogeneic CAR-NK cells | CD30 | Phase 1 | B2 Thymoma | Jun 2027 |
| EB-CAR5-NK CD5-targeted allogeneic CAR-NK cells | CD5 | Phase 1 | B2 Thymoma | Jun 2027 |
| EB-CARMSLN-NK Mesothelin-targeted allogeneic CAR-NK cells | MSLN | Phase 1 | B2 Thymoma | Jun 2027 |
| EB-DT-NK-UC101 Allogeneic dual-target Nectin-4/HER2 CAR-NK cells with inducible caspase-9 safety switch | NECTIN4, ERBB2 | Phase 1 | Bladder Cancer | Jun 2027 |
| EB-DTKN-401 Dual-target CSPG4/GD2 CAR-NK cells | CSPG4, GD2 | Phase 1 | Unresectable Melanoma | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07589530 | EB-NK-MF CAR-NK cells | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2027 |
| NCT07480928 | EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Oncology | Feb 2027 |
| NCT07480928 | EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Oncology | Feb 2027 |
| NCT07467863 | EB-G3B7-NK dual-target CAR-NK cells | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Feb 2027 |
| NCT07486089 | EB-G3B7-NK dual-target CAR-NK cells | Phase 1 | Breast Cancer (Locally Advanced or Metastatic) | Oncology | Feb 2027 |
| NCT07744256 | EB-DART-NK01 | Phase 1 | Small Cell Lung Cancer (SCLC) | Oncology | Feb 2027 |
| NCT07480213 | EB-DART-NK01 | Phase 1 | Small Cell Lung Cancer (SCLC) | Oncology | Feb 2027 |
| NCT07480954 | EB-NK-MF CAR-NK cells | Phase 1 | Epithelial Ovarian Cancer | Oncology | Feb 2027 |
| NCT07480941 | EB-G3B7-NK dual-target CAR-NK cells | Phase 1 | Glioblastoma | Oncology | Feb 2027 |
| NCT07551362 | EB-DT-CAR-NK | Phase 1 | Advanced Gastric Adenocarcinoma | Oncology | Mar 2027 |
| NCT07510828 | EB-PT-CAR-NK-S | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Mar 2027 |
| NCT07523555 | Autologous CD19/CD22 dual-target CAR-T module | Phase 1 | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Oncology | Mar 2027 |
| NCT07523555 | Autologous CD19/CD20 dual-target CAR-T module | Phase 1 | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Oncology | Mar 2027 |
| NCT07523555 | Autologous BCMA/CD19 dual-target CAR-T module | Phase 1 | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Oncology | Mar 2027 |
| NCT07523555 | Autologous BCMA/CD38 dual-target CAR-T module | Phase 1 | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Oncology | Mar 2027 |
| NCT07589517 | EB-DUO-CAR-NK-CEA/GCC | Phase 1 | Colorectal Cancer | Oncology | Mar 2027 |
| NCT07510815 | EB-MF-CAR-NK-01 | Phase 1 | Malignant Pleural Mesotheliomas | Oncology | Mar 2027 |
| NCT07500220 | EB-G3B7-NK dual-target CAR-NK cells | Phase 1 | Advanced Hepatocellular Carcinoma (HCC) | Oncology | Mar 2027 |
| NCT07641023 | EB-G3B7-NK dual-target CAR-NK cells | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Mar 2027 |
| NCT07510802 | EB-G3B7-NK dual-target CAR-NK cells | Phase 1 | Breast Cancer (Advanced/Metastatic) | Oncology | Mar 2027 |
| NCT07589543 | EB-DUALNK | Phase 1 | Epithelial Ovarian Cancer | Oncology | Mar 2027 |
| NCT07502287 | EB-DTNB-NK | Phase 1 | Relapsed Neuroblastoma | Oncology | Mar 2027 |
| NCT07617805 | EGFR/HER2 Dual-Target CAR-NK Cells | Phase 1 | Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Oncology | Mar 2027 |
| NCT07641049 | ETB-DualNK-01 | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Oncology | Mar 2027 |
| NCT07523542 | Autologous anti-CD19 CAR-T cells | Phase 1 | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS | Immunology | Mar 2027 |
| NCT07523542 | Autologous anti-BCMA CAR-T cells | Phase 1 | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS | Immunology | Mar 2027 |
| NCT07641036 | EB-HC01 dual-target CAR-NK cells | Phase 1 | Cholangiocarcinoma | Oncology | Mar 2027 |
| NCT07622940 | EBNK-1822H2 | Phase 1 | Recurrent or Metastatic Esophageal Adenocarcinoma | Oncology | Mar 2027 |
| NCT07551349 | EB-701/CA9-NK | Phase 1 | Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Oncology | Apr 2027 |
| NCT07627711 | EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Oncology | Apr 2027 |
| NCT07627711 | EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Oncology | Apr 2027 |
| NCT07551336 | EB-G3B7-NK dual-target CAR-NK cells | Phase 1 | Malignant Glioma | Oncology | Apr 2027 |
| NCT07523529 | Autologous dual-target CAR-T cells | Phase 1 | Advanced Unresectable | Oncology | Apr 2027 |
| NCT07617753 | EB-NK-MF CAR-NK cells | Phase 1 | Epithelial Ovarian Cancer | Oncology | Jun 2027 |
| NCT07627698 | EB-DTKN-401 | Phase 1 | Unresectable Melanoma | Oncology | Jun 2027 |
| NCT07492628 | EB-DT-NK-UC101 | Phase 1 | Bladder Cancer | Oncology | Jun 2027 |
| NCT07598955 | EB-CAR30-NK | Phase 1 | B2 Thymoma | Oncology | Jun 2027 |
| NCT07598955 | EB-CAR5-NK | Phase 1 | B2 Thymoma | Oncology | Jun 2027 |
| NCT07598955 | EB-CARMSLN-NK | Phase 1 | B2 Thymoma | Oncology | Jun 2027 |
| NCT07462650 | EB-DUO-CAR-NK-CEA/GCC | Phase 1 | Colorectal Cancer Metastatic | Oncology | Dec 2027 |
| NCT07493395 | Autologous anti-CD19 CAR-T cells | Phase 2 | Scleroderma, Systemic | Immunology | Jun 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.